

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850



Center for Medicare & Medicaid Innovation

DATE: February 28, 2022

TO: All Part D Sponsors and Pharmaceutical Manufacturers

FROM: Laura McWright, Deputy Director, Seamless Care Models Group
Center for Medicare & Medicaid Innovation

SUBJECT: Part D Senior Savings Model Pharmaceutical Manufacturer Participation and Part D Sponsor Request for Applications (RFA) for 2023

On January 27, 2022, CMS announced the RFA for non-participating pharmaceutical manufacturers interested in joining the Part D Senior Savings Model beginning in CY 2023. The Part D Senior Savings Model is a voluntary model that enables participating Part D enhanced alternative plans to lower Medicare beneficiaries' out-of-pocket costs for insulin to a maximum \$35 copay for a one-month's supply. Today, CMS is announcing the following for the Part D Senior Savings Model for CY 2023:

1. CY 2023 Pharmaceutical Manufacturer Participation;
2. CY 2023 Part D Sponsor RFA and Requirements; and,
3. CY 2023 Model Drug National Drug Code (NDC) List.

CY 2023 Pharmaceutical Manufacturer Participation

CMS again saw broad pharmaceutical manufacturer participation for CY 2023, with the following pharmaceutical manufacturers continuing participation in the Part D Senior Savings Model:

1. Eli Lilly and Company
2. Mannkind Corporation
3. Mylan Specialty L.P., a Viatris Company
4. Novo Nordisk, Inc. and Novo Nordisk Pharma, Inc.
5. Sanofi-Aventis U.S. LLC

CY 2023 Part D Sponsor RFA and Requirements

CMS is announcing the release of the CY 2023 Part D Senior Savings Model Part D Sponsor RFA. To apply, eligible Part D sponsors (including those who are currently participating) must submit the following by **no later than April 8th, 2022 at 11:59 PDT**:

- a completed application to participate in the Part D Senior Savings Model, found at the following link: https://cms.gov1.qualtrics.com/jfe/form/SV_8oB9AvgORDf1XF4.
- a completed Excel template, (entitled "CY2023 Application Parent Organization"), submitted via email and downloadable at the following link: <https://innovation.cms.gov/media/document/partd-seniorsav-cy23-parentorg>.

Applicants must submit complete and timely plan-specific information to be considered for participation. Please email the completed Excel template directly to the Part D Senior Savings Model mailbox at PartDSavingsModel@cms.hhs.gov. Links to the application are also included on the Model website. Please visit the Model website at <https://innovation.cms.gov/initiatives/part-d-savings-model> to view the RFA and application materials.

Model requirements for Part D sponsors include the following:

Model Drugs: Part D sponsors' participating enhanced alternative plan benefit packages are required to offer a maximum standard copay of \$35 for, at a minimum, a one-month's supply for both a vial dosage form at U-100 concentration and a pen dosage form at U-100 concentration for each of the following insulin types in the deductible, initial coverage, and coverage gap phases of the Part D benefit:

- rapid-acting insulin;
- short-acting insulin;
- intermediate-acting insulin; and
- long-acting insulin.

Part D sponsors meet Model requirements if the Part D sponsor's choice of formulary product line only has a vial dosage form or a pen dosage form for one of the above required Model drugs. As part of the application, CMS will require Part D sponsors to provide an excel template (titled "CY2023 Application Parent Organization" on the Model website (<https://innovation.cms.gov/media/document/partd-seniorsav-cy23-parentorg>) of all Model drugs included on the plan's formulary and attest that the associated copay will not exceed \$35 for a one-month's supply.

Additional Guidance on the Model: Additional model-specific guidance can be found in HPMS memos released on [4/9/2020](#) and [5/21/2020](#), as well as in the CY 2023 RFA. PDE Reporting Guidance for the Model can be found in HPMS memos released on [9/30/2021](#), [9/24/2021](#), and [4/27/2021](#). Unless otherwise noted in Model materials, Part D sponsors should continue to report prescription drug event data according to current CMS guidance located in HPMS and on the Customer Support Services Contract (CSSC) website. Please reach out to the PDSS Model Team at PartDSavingsModel@cms.hhs.gov with any additional questions.

Narrowed First Threshold Risk Corridor: As planned, there will not be an option for Part D sponsors to opt in to a narrowed first threshold risk corridor for CY 2023.

CY 2023 Model Drug NDCs

Please visit the Model website at <https://innovation.cms.gov/media/document/partd-seniorsav-ndclist-2023> for a complete list of Model Drug NDCs for CY 2023. (*Note: This list is separate from the current CY 2022 list applicable to current CY 2022 Model participants for CY 2022.*) The above participating manufacturers for CY 2023 included all marketed products under their respective labeler codes that are applicable covered Part D drugs that are, or contain, insulin, as classified in the American Hospital Formulary Service (AHFS) Drug Information or the DRUGDEX Information System compendia. Please note that the Model Drug list may be updated throughout the year and information on how Part D sponsors may update their plan selected Model drugs for CY 2023 will be provided to participating Part D sponsors when available.

Technical Application Guidance

When completing both parts of the Part D Sponsor Application, please note the following:

- **Complete one (1) application for each Parent Organization** based on your organization's Parent Organization designation as listed in HPMS. Please do not include multiple Parent Organizations that are listed separately in HPMS on the same application. When submitting, ensure that the name of your Parent Organization (including spelling, grammar, and spacing) is consistent with the Parent Organization name entered in HPMS, and matches on both the online application and the Excel template.
- **The contact information submitted for your Parent Organization in the online application should match one of the contacts listed in your Excel template.** The contact listed in the application does not have to be the Primary Contact on your Excel template.